Education
About Us
Working with TipRanks
Follow Us
PBE - ETF AI Analysis
Top Page
Invesco Dynamic Biotechnology & Genome ETF (PBE)
Rating:73Outperform
Price Target:―
Positive Factors
Leading Biotech and Genomics Holdings
The ETF’s largest positions are well-known biotechnology and genomics companies, several of which have shown strong or steady performance this year, helping support the fund.
Focused Health Care Exposure
Almost all assets are invested in the health care sector, giving investors targeted exposure to biotechnology and genome-related companies rather than a broad market mix.
Recent Short-Term Momentum
Despite slightly negative results so far this year, the ETF has shown strong performance over the last three months, suggesting improving short-term momentum.
Negative Factors
High Sector Concentration
With nearly all assets in health care and biotechnology, the fund is heavily exposed to swings in a single, often volatile sector.
Mixed Performance Among Top Holdings
Several of the largest positions have been weak or lagging this year, which has weighed on the ETF’s overall year-to-date results.
Relatively High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, meaning more of the returns are used to cover fees instead of staying with investors.
PBE vs. SPDR S&P 500 ETF (SPY)
AUM245.93M
RegionNorth America
Expense Ratio0.58%
Beta0.75
IssuerInvesco
Inception DateJun 23, 2005
Dividend Yield1.04%
Asset ClassEquity
Index TrackedDynamic Biotech & Genome Intellidex Index (AMEX)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume8,039
30 Day Avg. Volume7,163
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
104.08Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PBE Summary
The Invesco Dynamic Biotechnology & Genome ETF (PBE) tracks the Dynamic Biotech & Genome Intellidex Index, focusing on U.S. biotech and genomics companies working on new drugs, genetic testing, and advanced medical treatments. It holds well-known names like Amgen and Gilead Sciences, along with smaller innovators, giving investors a way to bet on the long-term growth of cutting-edge health care in a single fund. This can offer strong growth potential but also comes with higher risk, as biotech stocks can be very volatile and the ETF can go up and down sharply with news about drug trials and regulations.
How much will it cost me?The expense ratio for the Invesco Dynamic Biotechnology & Genome ETF (PBE) is 0.58%, which means you’ll pay $5.80 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on specialized biotechnology and genomic research companies that require more in-depth analysis and management.
What would affect this ETF?The Invesco Dynamic Biotechnology & Genome ETF (PBE) could benefit from advancements in biotechnology and genomic research, as well as increased demand for innovative healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, or economic downturns that could impact funding for biotech companies. The ETF’s focus on U.S.-based firms and top holdings like Vertex Pharmaceuticals and Gilead Sciences highlights its reliance on the performance of leading biotech innovators.
PBE Top 10 Holdings
PBE is a pure-play U.S. biotech fund, and its story right now is all about a handful of heavyweight drug makers and a few volatile innovators. Gilead, Amgen, Biogen, and Regeneron form the fund’s core engine, with all four generally rising and providing a steady lift. BioMarin has also been climbing, adding some extra spark. On the flip side, Illumina and Alnylam have been lagging, acting like a brake on returns. Overall, it’s a concentrated bet on large and mid-cap biotech rather than a broad health care mix.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| United Therapeutics | 5.94% | $14.83M | $23.48B | 76.01% | 79 Outperform | |
| Gilead Sciences | 5.28% | $13.19M | $184.43B | 29.83% | 78 Outperform | |
| Regeneron | 5.25% | $13.10M | $81.61B | 7.50% | 78 Outperform | |
| Illumina | 5.22% | $13.05M | $18.71B | 44.76% | 71 Outperform | |
| Amgen | 5.15% | $12.85M | $202.38B | 17.73% | 77 Outperform | |
| Alnylam Pharma | 5.08% | $12.69M | $42.76B | 35.03% | 60 Neutral | |
| Biogen | 5.07% | $12.65M | $27.65B | 31.15% | 74 Outperform | |
| Incyte | 4.99% | $12.45M | $19.11B | 41.06% | 81 Outperform | |
| BioCryst | 3.29% | $8.22M | $2.19B | 16.05% | 55 Neutral | |
| Protagonist Therapeutics | 3.18% | $7.94M | $6.19B | 62.40% | 68 Neutral |
PBE Technical Analysis
Negative
―
Price Trends
82.01
Negative
79.98
Negative
73.28
Positive
Market Momentum
-0.96
Positive
37.48
Neutral
34.11
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PBE, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 80.85, equal to the 50-day MA of 82.01, and equal to the 200-day MA of 73.28, indicating a neutral trend. The MACD of -0.96 indicates Positive momentum. The RSI at 37.48 is Neutral, neither overbought nor oversold. The STOCH value of 34.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBE.
PBE Peer Comparison
Comparison Results
Performance Comparison
PBE
Invesco Dynamic Biotechnology & Genome ETF
78.26
13.44
20.73%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
PJP
Invesco Dynamic Pharmaceuticals ETF
―
―
―
SBIO
ALPS Medical Breakthroughs ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents